Growth plus margin comfortably above forty is a useful test of a software company's health. Passing it says the business is balanced between expansion and efficiency. It says nothing about what the shares should cost, and that is where the argument usually goes wrong.
NET
Delayed
Healthy is not the same as cheap
The rule of forty is a description of the business. The valuation is a forecast of how long the growth lasts. A company can pass the test comfortably while its multiple already assumes it will pass it for a decade.
When growth decelerates even slightly, the business still looks healthy and the shares re-rate anyway, because the forecast changed.
What I'm watching
Revenue growth, and its rate of change
Operating margin, and whether it is rising as growth slows
The multiple against peers with similar growth
Where I stand
Short, on a valuation that assumes the growth rate holds for a very long time. The business passes the test; the price asks for more than the test can say.
What would change my mind
Growth reaccelerating from a larger base. That would justify the multiple on its own terms and make the forecast embedded in the price look reasonable.
The author holds no position in the instruments discussed. Opinion. Not advice. Not a financial promotion approved under FSMA s.21. Quote data is delayed. Past performance is not a reliable indicator of future results.
Comments
1 commentReading this again with hindsight. The risk section aged nicely.